45 listed sites: China (45) - 09 May `25ICP-332 tablets for nonsegmental vitiligo

ICP-332 tablets for nonsegmental vitiligo

Official title: A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo

Status: Recruiting now

Description:

Beijing InnoCare Pharma Tech Co., Ltd. plans to enroll about 603 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 12 to 75 may qualify. The study is recruiting at 45 listed sites in China.

Start date: May 09, 2025

Completion date: April 01, 2029

Organizer: Beijing InnoCare Pharma Tech Co., Ltd.

Contact: Flora Xiang, Doctor

Tel.: 021-52887775

Email: flora_xiang@vip.163.com

Link: https://clinicaltrials.gov/study/NCT07047612

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference ICP-332 tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Any link between vitiligo and military service?

    While there isn't specific research directly linking military service to the onset of vitiligo, it's critical to comprehend that vitiligo is a multifaceted disorder influenced b...

  • Is there a link between vitiligo and depression?

    Depression and anxiety are often linked with vitiligo, significantly impacting a person’s quality of life. The connection stems from the shared origin of the skin and brain duri...

  • How can I cure vitiligo?

    Right now, there is no universal "cure," but we have entered a new era of treatment. Today, managing vitiligo isn’t just about "hiding" it; it’s about sophisticated science that...